Mineralocorticoid receptor antagonists in the management of heart failure and resistant hypertension: A review

JAMA Cardiology

Volumn 1, Issue 5, 2016, Pages 607-612

  Flatt, David M ^a   Brown, Michael C ^a   Mizeracki, Adam M ^a   King, Bryan J ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

BODY MASS; CHRONIC KIDNEY FAILURE; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; EMERGENCY WARD; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERALDOSTERONISM; HYPERCALCIURIA; HYPOCALCEMIA; IMMUNOSUPPRESSIVE TREATMENT; LACTOSE INTOLERANCE; MEDICAL EDUCATION; NEW YORK HEART ASSOCIATION CLASS; POPULATION RESEARCH; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; ANALOGS AND DERIVATIVES; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HYPERKALEMIA; HYPERTENSION;

HEART FAILURE; HUMANS; HYPERKALEMIA; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85007213234     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.1878     Document Type: Review

References (80)

1. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol Metab. 1946;6:117-230.
2. Richards DW. Homeostasis: its dislocations and perturbations. Perspect Biol Med. 1960;3:238-251.
3. Kamalov G, Bhattacharya SK, Weber KT. Congestive heart failure: where homeostasis begets dyshomeostasis. J Cardiovasc Pharmacol. 2010;56 (3):320-328.
4. Pitt B, Zannad F, Remme WJ, et al; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717.
5. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14): 1309-1321.
6. Zannad F, McMurray JJ, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.
7. Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007;9 (1)(suppl 1):19-24.
8. Williams B, MacDonald TM, Morant S, et al; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068.
9. Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121(7):934-939.
10. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25(5): 563-575.
11. Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111(7):871-878.
12. Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33 (22):2782-2795.
13. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67(6): 1355-1364.
14. Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35(1): 138-147.
15. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120(6):893-901.
16. Zannad F, Alla F, Dousset B, Perez A, Pitt B; Rales Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation. 2000;102(22):2700-2706.
17. Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-e239.
18. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551.
19. Hernandez AF, Mi X, Hammill BG, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308(20):2097-2107.
20. Lipworth BJ, McDevitt DG, Struthers AD. Hypokalemic and ECG sequelae of combined β-agonist/diuretic therapy: protection by conventional doses of spironolactone but not triamterene. Chest. 1990;98(4):811-815.
21. Whitted AD, Stanifer JW, Dube P, et al. A dyshomeostasis of electrolytes and trace elements in acute stressor states: impact on the heart. Am J Med Sci. 2010;340(1):48-53.
22. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5 (6):720-726.
23. Bishu K, Deswal A, Chen HH, et al. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J. 2012;164(5):763-770.e3.
24. Pitt B, Pfeffer MA, Assmann SF, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370 (15):1383-1392.
25. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42.
26. Pfeffer MA, Braunwald E. Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiol. 2016;1(1):7-8.
27. Acelajado MC, Calhoun DA. Aldosteronism and resistant hypertension. Int J Hypertens. 2011;2011: 837817.
28. Maiolino G, Azzolini M, Rossi GP. Mineralocorticoid receptor antagonists therapy in resistant hypertension: time to implement guidelines! Front Cardiovasc Med. 2015;2:3.
29. Zia AA, Kamalov G, Newman KP, et al. From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation. Hypertens Res. 2010;33(11):1091-1101.
30. Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol. 2015;172(5): R191-R203.
31. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014;63(1):20-31.
32. Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012;44(3):170-176.
33. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002; 161(5):1773-1781.
34. Montezano AC, Touyz RM. Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research. Antioxid Redox Signal. 2014;20(1):164-182.
35. Münzel T, Gori T, Keaney JF Jr, Maack C, Daiber A. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J. 2015;36(38): 2555-2564.
36. Ahokas RA, Warrington KJ, Gerling IC, et al. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res. 2003;93(10):e124-e135.
37. 2 in peripheral blood mononuclear cells. Circulation. 2005;111(1):51-57.
38. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol. 2003; 285(2):H813-H821.
39. Resnick LM, Nicholson JP, Laragh JH. Calcium metabolism and the renin-aldosterone system in essential hypertension. J Cardiovasc Pharmacol. 1985;7(suppl 6):S187-S193.
40. Resnick L. Calcium metabolism, renin activity, and the antihypertensive effects of calcium channel blockade. Am J Med. 1986;81(6A):6-14.
41. Chhokar VS, Sun Y, Bhattacharya SK, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol. 2004;287(5):H2023-H2026.
42. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol. 1994;14(3):219-231.
43. Fujita T, Palmieri GM. Calcium paradox disease: calcium deficiency prompting secondary hyperparathyroidism and cellular calcium overload. J Bone Miner Metab. 2000;18(3):109-125.
44. Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290 (1):H286-H294.
45. Cheema Y, Sherrod JN, Zhao W, et al. Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol. J Cardiovasc Pharmacol. 2011;58(1):80-86.
46. Shahbaz AU, Kamalov G, Zhao W, et al. Mitochondria-targeted cardioprotection in aldosteronism. J Cardiovasc Pharmacol. 2011;57(1): 37-43.
47. Goodwin KD, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. Am J Med Sci. 2006;332(2):73-78.
48. Selektor Y, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. Am J Med Sci. 2008;335(2):105-110.
49. Ramires FJA, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol. 1998;30(3):475-483.
50. Rubattu S, Pagliaro B, Pierelli G, et al. Pathogenesis of target organ damage in hypertension: role of mitochondrial oxidative stress. Int J Mol Sci. 2014;16(1):823-839.
51. Dikalov SI, Ungvari Z. Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol. 2013;305(10):H1417-H1427.
52. Stefenelli T, Pacher R, Woloszczuk W, Glogar D, Kaindl F. Parathyroid hormone and calcium behavior in advanced congestive heart failure [in German]. Z Kardiol. 1992;81(2):121-125.
53. Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 1994;96(1):35-41.
54. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997; 103(3):197-207.
55. Schmid C, Kiowski W. Hyperparathyroidism in congestive heart failure. Am J Med. 1998;104(5): 508-509.
56. Ogino K, Ogura K, Kinugasa Y, et al. Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. J Clin Endocrinol Metab. 2002;87(10):4722-4727.
57. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Körfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41 (1):105-112.
58. Khouzam RN, Dishmon DA, Farah V, Flax SD, Carbone LD, Weber KT. Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure. Am J Med Sci. 2006;331(1):30-34.
59. Laguardia SP, Dockery BK, Bhattacharya SK, Nelson MD, Carbone LD, Weber KT. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci. 2006;332(3):112-118.
60. Alsafwah S, Laguardia SP, Nelson MD, et al. Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure. Am J Med Sci. 2008;335(4):292-297.
61. Sugimoto T, Tanigawa T, Onishi K, et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart. 2009;95(5): 395-398.
62. Garakyaraghi M, Kerdegari M, Siavash M. Calcium and vitamin D status in heart failure patients in Isfahan, Iran. Biol Trace Elem Res. 2010; 135(1-3):67-73.
63. Altay H, Zorlu A, Binici S, et al. Relation of serum parathyroid hormone level to severity of heart failure. Am J Cardiol. 2012;109(2):252-256.
64. Altay H, Zorlu A, Bilgi M, Erol T, Yilmaz MB. Usefulness of parathyroid hormone as a predictor of heart failure with preserved ejection fraction. Biomarkers. 2012;17(5):447-454.
65. Zittermann A, Fuchs U, Kuhn J, et al. Parameters of mineral metabolism predict midterm clinical outcome in end-stage heart failure patients. Scand Cardiovasc J. 2011;45(6):342-348.
66. Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen JE. Parathyroid hormone and vitamin D: markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011;13(6): 626-632.
67. Gruson D, Ahn SA, Rousseau MF. Multiple biomarker strategy based on parathyroid hormone and natriuretic peptides testing for improved prognosis of chronic heart failure. Peptides. 2015; 64:24-28.
68. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78(3):385-390.
69. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8(9):884-893.
70. Brown J, de Boer IH, Robinson-Cohen C, et al. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2015;100(2):490-499.
71. Muller ME, Forni Ogna V, Maillard M, et al. Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system. Pflugers Arch. 2015; 467(12):2413-2421.
72. Zia AA, Komolafe BO, Moten M, et al. Supplemental vitamin D and calcium in the management of African Americans with heart failure having hypovitaminosis D. Am J Med Sci. 2011;341(2):113-118.
73. Terrovitis J, Zotos P, Kaldara E, et al. Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. Eur J Heart Fail. 2012;14(3):326-332.
74. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation. 2008;118 (19):1946-1952.
75. Carbone LD, Cross JD, Raza SH, et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J Am Coll Cardiol. 2008;52(2):135-138.
76. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31(13):1591-1598.
77. Hagström E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119(21):2765-2771.
78. Hagström E, Ingelsson E, Sundström J, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12(11):1186-1192.
79. Björkman M, Sorva A, Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology. 2009;55(6):601-606.
80. Deo R, Katz R, Shlipak MG, et al. Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension. 2011;58(6):1021-1028.